X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The financing will be used to conduct the Dal-GenE-2 confirmatory trial evaluating the potential of Dal-302 (dalcetrapib) to reduce the occurrence of fatal and non-fatal myocardial infarction in North America under a Special Protocol Assessment agreement with the FDA.
Lead Product(s): Dalcetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Dal-302
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Québec government
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing September 13, 2023
Details:
On fatal and non-fatal MI, the DAL-301 (dalcetrapib) treatment showed a relative risk reduction of 21% compared to placebo (5.9% vs. 7.3%; HR 0.79; 95% CI 0.65-0.96; p=0.02). Dalcetrapib was safe and well tolerated in the dal-GenE trial.
Lead Product(s): Dalcetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: DAL-301
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 21, 2022
Details:
The independent dal-GenE Data and Safety Monitoring Board (DSMB) recommends the dal-GenE pivotal outcomes trial should continue as planned with no modifications. This is an important milestone for DalCor and for cardiovascular patients with the ADCY9 AA genotype.
Lead Product(s): Dalcetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
